（文章来源：证券日报） 证券日报网讯 9月8日晚间，麦迪科技发布公告称，公司"苏州麦迪斯顿医疗科技股份有限公司—第三期 员工持股计划"中所持有的1，037，300股公司股票已于2025年9月5日以非交易过户的方式过户至"苏州 麦迪斯顿医疗科技股份有限公司回购专用证券账户"，过户价格为5.29元/股（含税）。截至本公告披露 日，公司本次员工持股计划账户持有公司股份0股，占公司总股本比例为0%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日召开的第四届董事会第三十四次会议审议通过了《关于回购公司第三期员 工持股计划未解锁股份暨第三期员工持股计划终止的议案》，根据中国证监会《关 于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》《上市公司股份回购规则》及《公司章程》的相 关规定，公司拟回购第三期员工持股计划（以下简称"本次员工持股计划"）未 能解锁的 1,037,300 股公司股票。具体内容详见公司于 2025 年 8 月 20 日披露的 《麦迪科技关于回购公司第三期员工持股计划未解锁股份暨第三期员工持股计 划终止的公告》（公告编号 2025-054）。 根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》《上市公司股份回购规则》及《公 司章程》的要求，现将公司第三期员工持股计划（以下简称"本次员工持股计划"） 股份回购 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-059 苏州麦迪斯顿医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 公司募集资金现金管理到期赎回情况 公司于 2025 年 8 月 26 日向浙商银行苏州分行营业部办理了两笔银行七天通 知存款业务。截至本公告披露日，公司已将上述产品赎回，收回本金共 10,500 万元，获得理财收益 2.84 万元。 上述产品具体情况如下： 单位：人民币万元 | 受托方 | 产品名 | 认购金 | 起息日 | 到期日 | 赎回金 | 理财收 | | --- | --- | --- | --- | --- | --- | --- | | | 称 | 额 | | | 额 | 益 | | 浙商银行 苏州分行 | 银行七 天通知 | 7,000 | 2025 年 8 月 26 日 | 2025 年 9 月 8 日 | 7,000 | 1.90 | | 营业部 | 存款 | | | | | | | 浙商银行 | 银行 ...

Market Performance - On September 5, the AI medical sector rose by 1.53%, with Yaoshi Technology leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - The top-performing stocks in the AI medical sector included: - Yaoshi Technology (300725) with a closing price of 44.21, up 3.85% [1] - ZheShu Culture (600633) with a closing price of 14.44, up 3.74% [1] - MaiDi Technology (603990) with a closing price of 14.64, up 3.24% [1] - Other notable stocks included Hongbo Pharmaceutical (301230) at 37.89, up 3.21%, and Jiahe Meikang (688246) at 31.20, up 2.80% [1] Capital Flow - The AI medical sector saw a net inflow of 56.49 million yuan from institutional investors, while retail investors experienced a net outflow of 50.12 million yuan [2] - The capital flow for specific stocks showed: - Meinian Health (002044) had a net inflow of 39.11 million yuan from institutional investors [3] - MaiDi Technology (603990) had a net inflow of 19.26 million yuan from institutional investors [3] - ZheShu Culture (600633) had a net inflow of 5.19 million yuan from institutional investors [3]

Core Viewpoint - The company has successfully turned around its financial performance by divesting from its photovoltaic business and focusing on its core medical information technology sector, leading to significant profit growth and improved operational efficiency [1][2]. Financial Performance - In the first half of 2025, the company achieved a net profit attributable to shareholders of 28.33 million yuan, a substantial increase of 137.11% year-on-year, marking a return to profitability [1]. - The company's asset-liability ratio has significantly decreased, and cash flow conditions have improved following the divestment of the photovoltaic business [2]. Business Structure - The core business of medical information technology remains stable, with ongoing innovation and expansion into new areas such as health care robots, which are currently in the scenario validation phase [2]. - The company has developed a comprehensive smart robot health care solution that integrates intelligent interaction, big data analysis, and health management, targeting elderly and rehabilitation patients [2]. Research and Development Investment - The company plans to invest 43.55 million yuan in new projects focused on innovative product development, including low-altitude medical rescue and smart medical service robots [3]. - An additional 130 million yuan is earmarked for upgrading products and services based on large model artificial intelligence technology, aiming to enhance the existing smart medical product system [3]. Strategic Focus - The company emphasizes that medical information technology remains its core value, having established applications in over 2,400 medical institutions across the country, which provides a strong foundation and competitive advantage [3]. - The company is strategically positioned in the auxiliary reproductive business, with its Haikou Mary Hospital being the second private hospital in Hainan to obtain a reproductive license, indicating a stable operation in a scarce market [4]. Synergy and Market Opportunities - The company is exploring synergies between its various business segments, leveraging data and technology to enhance overall competitiveness and core value [4]. - The strategic focus on health care robots and low-altitude emergency rescue aligns with national trends, providing significant market opportunities in elder care and rehabilitation [4].

Core Insights - The robotics sector showed positive performance in H1 2025, with 120 companies generating total revenue of 288.83 billion yuan, a year-on-year increase of 13.81%, and a net profit of 21.62 billion yuan, also up by 13.72% [1][2] Revenue and Profitability - In H1 2025, 106 out of 120 companies in the robotics sector reported profits, with a total net profit of 21.62 billion yuan, reflecting a 13.72% increase year-on-year [1] - In Q2 2025, the sector achieved revenue of 153.24 billion yuan, a 14.65% increase year-on-year, with net profit reaching 11.37 billion yuan, up by 6.80% [1] Segment Performance - The fastest profit growth was observed in the thermal components and brain-related segments, while the joint assembly, motor, screw, and reducer segments showed substantial and stable profit growth [2] - Notably, seven companies, including Zhengyu Industrial and Daye Co., saw net profit growth rates exceeding 100% in H1 2025, with Zhengyu Industrial achieving a remarkable 1133.26% growth in Q2 2025 [2] Margin and Cost Trends - The average gross margin for the robotics sector in H1 2025 was 21.94%, with a net margin of 7.48% and a period expense ratio of 7.22% [3] - The core components segment exhibited the highest profitability, with a gross margin of 22.54% and a net margin of 9.31% in H1 2025 [3] Technological Advancements - The pace of technological iteration in robotics accelerated in H1 2025, with advancements in lightweight materials like PEEK and improvements in energy efficiency through new technologies [4] - Significant developments were noted in the upper body freedom and dexterity of robots, enhancing their capabilities for tasks such as soccer [4] Commercialization and Orders - The commercialization of robotics progressed rapidly, with notable orders including a billion-yuan contract from China Mobile and a significant procurement project from UBTECH [5] - The collaboration within the robotics supply chain deepened, with cumulative orders from subsidiaries of Bozhong Precision exceeding 100 million yuan [5] Investment Recommendations - The second half of 2025 should focus on new technology iterations and the "ticket pricing" trend in the supply chain, particularly for Tesla and other key players [6] - Key components to watch include tactile sensors, harmonic reducers, and PEEK materials, which are expected to see increased adoption due to cost reductions and leading companies' demonstration effects [7]

2022年5月23日，出让方与皓祥控股签署了《股份转让协议》，根据协议约 定，出让方将其持有的公司股票合计12,631,936股转让给皓祥控股。具体内容详 见公司于2022年5月24日披露的《关于实际控制人及一致行动人、其他股东签署< 股份转让协议>、公司签署附条件生效的股份认购协议暨控制权变更的进展公告》 （公告编号：2022-033）及于2022年5月27日披露的《简式权益变动报告书》《详 式权益变动报告书》及财务顾问核查意见。 证券代码：603990 证券简称：麦迪科技 公告编号：2025-057 苏州麦迪斯顿医疗科技股份有限公司 关于股东业绩承诺实现情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司""上市公司"或"麦 迪科技"）原实际控制人翁康及其他股东严黄红、汪建华、傅洪（以下合称"出 让方"）与绵阳皓祥控股有限责任公司（以下简称"皓祥控股"）于2022年5月 23日签订了《股权转让协议》，并对公司2022-2024年度业绩作出业绩承诺。现 ...

Group 1 - The core viewpoint of the news is that Madi Technology (603990) has shown a mixed performance in its latest financial results, with a significant drop in revenue but a notable increase in net profit [1] - As of August 25, 2025, Madi Technology's stock closed at 15.36 yuan, with a slight increase of 0.26% and a trading volume of 178,400 hands, amounting to 273 million yuan [1] - The company experienced a net outflow of main funds amounting to 25.92 million yuan, which represents 9.49% of the total transaction amount, indicating a cautious sentiment among investors [1] Group 2 - For the latest financial period ending in mid-2025, Madi Technology reported total operating revenue of 135 million yuan, a decrease of 47.24% year-on-year, while net profit attributable to shareholders was 28.33 million yuan, an increase of 137.11% [1] - The company has a current ratio of 2.509, a quick ratio of 2.388, and a debt-to-asset ratio of 33.30%, indicating a strong liquidity position [1] - Madi Technology, established in 2009 and located in Suzhou, has a registered capital of 3.06 billion yuan and has made investments in 9 companies, participated in 3,041 bidding projects, and holds 84 trademarks and 169 patents [2]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-055 苏州麦迪斯顿医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开方式：视频直播和网络互动 投资者可于 2025 年 08 月 26 日(星期二)至 09 月 01 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 suzhoumedi001@medicalsystem.cn 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）已于 会议召开时间：2025 年 09 月 02 日(星期二) 下午 13:15-14:45 会议参与方式一：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/）； 会议参与方式二： "麦迪科技投资者关系"小程序，通过微信 搜索"麦迪科技投资者关系"或微信扫一扫以下二维码参与会议 2025 年 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第四届董事会第三十一次会议、第四届监事会第十五次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影 响募集资金投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金 不超过人民币 2 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以 滚动使用，用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款等 安全性高的保本型产品，不得用于证券投资。公司董事会、监事会及保荐机构已 分别对前述事项发表了同意的意见。具体内容详见公司于 2025 年 4 月 30 日披露 的《关于使用部分闲置募集资金进行现金管理的公告》(公告编号：2025-025)。 一、 公司募集资金现金管理到期赎回情况 公司于 2025 年 7 月 22 日向浙商银行苏州分行营业部办理了两笔结构性存款 业务。截至本公告披露日，公司已将上述产品赎回，收回本金共 10,500 ...